de Avila Ana Isabel, Moreno Elena, Perales Celia, Domingo Esteban
Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, E-28049, Madrid, Spain.
Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, E-28049, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Liver Unit, Internal Medicine, Laboratory of Malalties Hepàtiques, Vall d'Hebron Institut de Recerca-Hospital Universitari Vall d'Hebron (VHIR-HUVH), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain.
Virus Res. 2017 Apr 2;233:105-112. doi: 10.1016/j.virusres.2017.03.014. Epub 2017 Mar 18.
Antiviral agents are increasingly considered an option for veterinary medicine. An understanding of their mechanism of activity is important to plan their administration either as monotherapy or in combination with other agents. Previous studies have shown that the broad spectrum antiviral agent favipiravir (T-705) and its derivatives T-1105 and T-1106 are efficient inhibitors of foot-and-mouth disease virus (FMDV) replication in cell culture and in vivo. However, no mechanism for their activity against FMDV has been proposed. In the present study we show that favipiravir (T-705) can act as a lethal mutagen for FMDV in cell culture. Evidence includes virus extinction associated with increase in mutation frequency in the mutant spectrum of 860 residues of the 3D (polymerase)-coding region, and a decrease of specific infectivity while the consensus nucleotide sequence of the region analyzed remained invariant. The mutational spectrum evoked by favipiravir differs from that observed with other viruses in that no predominant transition type is observed, indicating that a movement towards A,U- or G,C-rich regions of sequence space is not a prerequisite for virus extinction. We discuss prospects for the use of favipiravir to assist in the control of FMDV, and its possible broader use in veterinary medicine as an extension of its current status as antiviral agent for human influenza virus.
抗病毒药物越来越被视为兽医学的一种选择。了解其作用机制对于规划其作为单一疗法或与其他药物联合使用的给药方式很重要。先前的研究表明,广谱抗病毒药物法匹拉韦(T-705)及其衍生物T-1105和T-1106在细胞培养和体内均是口蹄疫病毒(FMDV)复制的有效抑制剂。然而,尚未有人提出它们抗FMDV的作用机制。在本研究中,我们表明法匹拉韦(T-705)在细胞培养中可作为FMDV的致死诱变剂。证据包括与3D(聚合酶)编码区860个残基的突变谱中突变频率增加相关的病毒灭绝,以及在分析区域的共有核苷酸序列保持不变的情况下特异性感染性的降低。法匹拉韦诱发的突变谱与其他病毒观察到的不同,因为未观察到主要的转换类型,这表明向富含A、U或G、C的序列空间区域移动不是病毒灭绝的先决条件。我们讨论了使用法匹拉韦协助控制FMDV的前景,以及它作为人类流感病毒抗病毒药物的现有地位的延伸在兽医学中可能更广泛应用的可能性。